Welcome To Welox Pharma WHO-GMP | ISO 9001:2015
Translated into:
Welcome To Welox Pharma WHO-GMP | ISO 9001:2015
Introduction OF FACTOCEL VIII 500IU:
Antihaemophilic Factor VIII (Factor VIII) is a crucial protein involved in the blood clotting process. It is essential for individuals with hemophilia A, a genetic disorder characterized by the lack or deficiency of Factor VIII, resulting in prolonged bleeding and difficulty in clotting.
Uses OF FACTOCEL VIII 500IU:
Factor VIII is primarily used to treat and manage bleeding episodes in people with hemophilia A. It promotes normal blood clotting, preventing excessive bleeding or hemorrhage associated with injuries, surgeries, or other medical procedures.
Benefits OF FACTOCEL VIII 500IU:
Hemophilia Management: Factor VIII replacement therapy is vital for managing and preventing bleeding episodes in individuals with hemophilia A, allowing them to lead more normal and active lives.
Improved Quality of Life: By providing the necessary clotting factor, Factor VIII reduces the severity and duration of bleeding, enabling individuals to participate in daily activities and engage in physical and social pursuits with fewer restrictions.
Prevention of Complications: Timely and appropriate Factor VIII administration helps prevent joint damage, internal bleeding, and other complications associated with hemophilia A.
Mechanism of Action OF FACTOCEL VIII 500IU:
Factor VIII is a co-factor for Factor IXa in the clotting cascade, ultimately leading to the formation of a stable blood clot. The coagulation process involves multiple steps, and Factor VIII plays a critical role in one of these steps, aiding in the conversion of Factor X to Factor Xa. Factor Xa is necessary for the conversion of prothrombin to thrombin, which, in turn, converts fibrinogen to fibrin, the key component of blood clots.